BOOKS LISTS DIARY ACTIVITY REVIEWS STATS MEMBERS

Yükleniyor

Track books, build shelves, write reviews, make public lists, and follow readers whose taste you trust.

Explore

Browse books
Lists
Diary
Stats

Community

Reader activity
Public lists
Reviews
Members

Newsletter

Get weekly book recommendations.

© 2026 Cilt. All rights reserved.

Yükleniyor

Yazar

grzegorz s nowakowski

4 cilt bulundu.

Cilt sonuçları

American Society of Hematology Self-Assessment Program

American Society of Hematology Self-Assessment Program

Timothy Graubert, James R. Cook, Laura Scheuttpelz, Donald M. Arnold, Adam Cuker, Cindy Neunert, Keith R. McCrae, Margaret Ragni, Sarah O'Brien, Murat Arcasoy, Gary Lyman, Marc J. Kahn, Lawrence A. Solberg, Jecko Thachil, Timothy James Littlewood, Sioban Keel, Charles T. Quinn, Charles H. Packman, Stephan Moll, David Garcia, David P. Steensma, Anjali Sharathkumar, Jorge Di Paola, Amy D. Shapiro, · Yayınevi bilinmiyor

637 sayfa · 2013-06-04

Hematology

CiltRE-MIND2: Comparative Effectiveness of Tafasitamab Plus Lenalidomide Versus Polatuzumab Vedotin/bendamustine/rituximab (pola-BR), CAR-T Therapies, and Lenalidomide/rituximab (R2) Based on Real-world Data in Patients with Relapsed/refractory Diffuse Large B-cell LymphomaGrzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Andre Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Heß, Gilles Salles

RE-MIND2: Comparative Effectiveness of Tafasitamab Plus Lenalidomide Versus Polatuzumab Vedotin/bendamustine/rituximab (pola-BR), CAR-T Therapies, and Lenalidomide/rituximab (R2) Based on Real-world Data in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma

CiltCorrection To: RE-MIND2: Comparative Effectiveness of Tafasitamab Plus Lenalidomide Versus Polatuzumab Vedotin/bendamustine/rituximab (pola-BR), CAR-T Therapies, and Lenalidomide/rituximab (R2) Based on Real-world Data in Patients with Relapsed/refractory Diffuse Large B-cell LymphomaGrzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Andre Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Heß, Gilles Salles

Correction To: RE-MIND2: Comparative Effectiveness of Tafasitamab Plus Lenalidomide Versus Polatuzumab Vedotin/bendamustine/rituximab (pola-BR), CAR-T Therapies, and Lenalidomide/rituximab (R2) Based on Real-world Data in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, , · Yayınevi bilinmiyor

CiltASH-SAPBilinmeyen yazar

Bilinmeyen yazar · Yayınevi bilinmiyor

Sayfa sayısı yok · 2016

Kategori yok

Suzanne Bakdash,

Dan S. Kaufman,

David T. Scadden,

Geoffrey L. Uy,

Inderjeet Dokal,

Phillip Scheinberg,

B. Douglas Smith,

Daniel J. DeAngelo,

Kristie A. Blum,

Kerry Joanne Savage,

Grzegorz S. Nowakowski,

Vicki A. Morrison,

Irene Ghobrial,

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Andre Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Heß, Gilles Salles · Yayınevi bilinmiyor

Sayfa sayısı yok · 2023

Kategori yok

Pier Luigi Zinzani,

Judith Trotman,

Lorenzo Sabatelli,

Mark Andre Winderlich,

Andrea Sporchia,

Nuwan C. Kurukulasuriya,

Sayfa sayısı yok · 2023

Kategori yok